Intranasal Insulin Treatment in Patients With Schizophrenia
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study is an 8-week, randomized, double-blind, placebo-controlled trial of intranasal
insulin as an adjunctive therapy, with a 4-week follow-up, in 60 non-diabetic schizophrenia
subjects to examine insulin's effect on psychopathology and cognition. In addition, the study
will examine insulin's effects on weight, food intake, resting energy expenditure, and body
composition.
Phase:
Phase 4
Details
Lead Sponsor:
University of Massachusetts, Worcester
Collaborators:
Eli Lilly and Company National Alliance for Research on Schizophrenia and Depression